Atea Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Atea Pharmaceuticals Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reports zero beneficial ownership in Atea Pharmaceuticals Inc. following an internal realignment and disaggregated reporting.
NASDAQ
BML Investment Partners, L.P. and Leonard Braden Michael have reported beneficial ownership of 9.9% of Atea Pharmaceuticals, Inc.'s common stock.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an Amendment No. 8 to Schedule 13G, disclosing a beneficial ownership of 11.6% in ATEA Pharmaceuticals Inc. common stock as of November 28, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a 6.7% beneficial ownership stake in ATEA Pharmaceuticals Inc. common stock as of June 30, 2025.
NASDAQ
JPM Partners LLC and Jean-Pierre Sommadossi have disclosed significant beneficial ownership stakes in Atea Pharmaceuticals, Inc., with Dr. Sommadossi holding 10.1% of the common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 7.1% Passive Stake in Atea Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Atea Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: EcoR1 Capital Amends Stake in Atea Pharmaceuticals, Disclosing 4.0% Beneficial Ownership
EcoR1 Capital, LLC and affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership of 4.0% of Atea Pharmaceuticals, Inc.'s common stock as of December 31, 2024.